William T Abraham

List of Publications by Citations

Source: https://exaly.com/author-pdf/9949656/william-t-abraham-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185
papers

9,901
citations

43
p-index

97
g-index

191
ext. papers

8
avg, IF

6.09
L-index

#	Paper	IF	Citations
185	Transcatheter Mitral-Valve Repair in Patients with Heart Failure. <i>New England Journal of Medicine</i> , 2018 , 379, 2307-2318	59.2	1160
184	Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. <i>Lancet, The</i> , 2011 , 377, 658-66	40	982
183	Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 1834-1843	15.1	851
182	In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). <i>Journal of the American College of Cardiology</i> , 2005 , 46, 57-64	15.1	608
181	Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). <i>Journal of the American College of Cardiology</i> , 2008 , 52, 347-56	15.1	394
180	Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. <i>Circulation</i> , 2004 , 110, 2864-8	16.7	393
179	Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. <i>Lancet, The</i> , 2016 , 387, 453	-6 ⁴ O	296
178	Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 935-44	7.6	256
177	Cardiac resynchronization therapy for heart failure. <i>Circulation</i> , 2003 , 108, 2596-603	16.7	241
176	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017 , 376, 1956-1964	59.2	185
175	Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2016 , 374, 1521-32	59.2	159
174	Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). <i>Congestive Heart Failure</i> , 2011 , 17, 51-5		155
173	Sleep disordered breathing and post-discharge mortality in patients with acute heart failure. <i>European Heart Journal</i> , 2015 , 36, 1463-9	9.5	152
172	Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC: Heart Failure, 2015 , 3, 487-496	7.9	139
171	Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2000-2007	15.1	136
170	Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1875-1886	15.1	124
169	CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. <i>Journal of Cardiac Failure</i> , 2011 , 17, 3-10	3.3	117

168	Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. <i>Lancet, The</i> , 2016 , 388, 974-82	40	96	
167	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. <i>JACC: Heart Failure</i> , 2018 , 6, 874-883	7.9	91	
166	Phrenic nerve stimulation for the treatment of central sleep apnea. JACC: Heart Failure, 2015, 3, 360-36	5 9 7.9	89	
165	Echocardiographic Outcomes After Transcatheter Leaflet Approximation in Patients With Secondary Mitral Regurgitation: The COAPT Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2969-2979	15.1	88	
164	Mechanisms and clinical consequences of untreated central sleep apnea in heart failure. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 72-84	15.1	86	
163	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 29-40	15.1	86	
162	Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring. <i>JACC: Heart Failure</i> , 2016 , 4, 333-44	7.9	82	
161	Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor. <i>Circulation</i> , 2017 , 135, 1509-1517	16.7	81	
160	MG53-mediated cell membrane repair protects against acute kidney injury. <i>Science Translational Medicine</i> , 2015 , 7, 279ra36	17.5	70	
159	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018 , 20, 888-895	12.3	65	
158	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2490-2500	15.1	65	
157	Implantable Hemodynamic Monitoring for Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 389-398	15.1	62	
156	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2015 , 17, 1066-74	12.3	62	
155	Evaluation of remote dielectric sensing (ReDS) technology-guided therapy for decreasing heart failure re-hospitalizations. <i>International Journal of Cardiology</i> , 2017 , 240, 279-284	3.2	61	
154	Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. <i>American Heart Journal</i> , 2018 , 205, 1-11	4.9	55	
153	Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	54	
152	Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS Post-Approval Study. <i>Circulation: Heart Failure</i> , 2020 , 13, e006863	7.6	51	
151	Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2428-2445	15.1	50	

150	Pulmonary Artery Pressure-Guided Heart Failure Management Reduces 30-Day Readmissions. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	50
149	Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). <i>Journal of Cardiac Failure</i> , 2015 , 21, 479-88	3.3	50
148	The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. <i>European Heart Journal</i> , 2015 , 36, 1983-9	9.5	48
147	Combinatorial pharmacogenetic interactions of bucindolol and 11 , 2 C adrenergic receptor polymorphisms. <i>PLoS ONE</i> , 2012 , 7, e44324	3.7	48
146	Pulmonary hypertension related to left heart disease: insight from a wireless implantable hemodynamic monitor. <i>Journal of Heart and Lung Transplantation</i> , 2015 , 34, 329-37	5.8	47
145	The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018 , 20, 780-791	12.3	47
144	Percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure: three-year outcomes of the PARACHUTE first-in-human study. <i>Circulation: Heart Failure</i> , 2014 , 7, 752-8	7.6	44
143	Devices in the management of advanced, chronic heart failure. <i>Nature Reviews Cardiology</i> , 2013 , 10, 98-	- 1:140 8	44
142	Income Inequality and Outcomes in Heart[Failure: A Global Between-Country Analysis. <i>JACC: Heart Failure</i> , 2019 , 7, 336-346	7.9	42
141	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020 , 41, 2109-2117	9.5	42
140	Interatrial Shunting for Heart Failure: Early and Late Results From the First-in-Human Experience With the V-Wave System. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 2300-2310	5	42
139	Baroreflex Activation Therapy in Patients With Heart[Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1-13	15.1	41
138	Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 1746-1754	12.3	41
137	Prevention of atrial fibrillation by bucindolol is dependent on the betaB89 Arg/Gly adrenergic receptor polymorphism. <i>JACC: Heart Failure</i> , 2013 , 1, 338-344	7.9	39
136	Center of excellence for mobile sensor data-to-knowledge (MD2K). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015 , 22, 1137-42	8.6	38
135	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	37
134	Burden of atrial fibrillation and poor rate control detected by continuous monitoring and the risk for heart failure hospitalization. <i>American Heart Journal</i> , 2012 , 164, 616-24	4.9	36
133	3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1029-1040	15.1	36

132	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021 , 42, 700-7	10 ^{9.5}	35	
131	Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials. <i>European Journal of Heart Failure</i> , 2017 , 19, 426-433	12.3	34	
130	Similar hemodynamic decongestion with vasodilators and inotropes: systematic review, meta-analysis, and meta-regression of 35 studies on acute heart failure. <i>Clinical Research in Cardiology</i> , 2016 , 105, 971-980	6.1	33	
129	Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 monthsQexperience with the remed\(\textit{S}\)ystem. European Journal of Heart Failure, 2016, 18, 1386-1393	12.3	32	
128	Current challenges for clinical trials of cardiovascular medical devices. <i>International Journal of Cardiology</i> , 2014 , 175, 30-7	3.2	31	
127	Disease management: remote monitoring in heart failure patients with implantable defibrillators, resynchronization devices, and haemodynamic monitors. <i>Europace</i> , 2013 , 15 Suppl 1, i40-i46	3.9	31	
126	Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial. <i>European Heart Journal</i> , 2016 , 37, 49-59	9.5	30	
125	A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. <i>American Heart Journal</i> , 2008 , 156, 641-648.e1	4.9	30	
124	Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. <i>Clinical and Translational Science</i> , 2010 , 3, 249-53	4.9	29	
123	Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea. <i>Sleep</i> , 2019 , 42,	1.1	27	
122	Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis. <i>European Journal of Heart Failure</i> , 2020 , 22, 1803-1813	12.3	27	
121	Trials of implantable monitoring devices in heart failure: which design is optimal?. <i>Nature Reviews Cardiology</i> , 2014 , 11, 576-85	14.8	27	
120	Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. <i>Kidney International</i> , 2012 , 82, 1215-22	9.9	27	
119	A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with moderately reduced left ventricular ejection fraction and a narrow QRS duration: study rationale and design. <i>Journal of Cardiac Failure</i> , 2015 , 21, 16-23	3.3	25	
118	Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. <i>Kidney International</i> , 2012 , 82, 1223-30	9.9	25	
117	Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). <i>American Heart Journal</i> , 2019 , 214, 18-27	4.9	24	
116	Design and rationale of haemodynamic guidance with CardioMEMS in patients with a left ventricular assist device: the HEMO-VAD pilot study. <i>ESC Heart Failure</i> , 2019 , 6, 194-201	3.7	24	
115	Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With CardiaclResynchronization: Results From the REVERSE Trial. <i>JACC: Heart Failure</i> , 2017 , 5, 169-178	7.9	22	

114	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020 , 5, 432-441	16.2	22
113	The prevalence and importance of frailty in heart failure with reduced ejection fraction that analysis of PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020 , 22, 2123-2133	12.3	22
112	Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 443-453	15.1	22
111	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , 2019 , 21, 577-587	12.3	22
110	Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease: insights from a wireless pulmonary artery pressure monitoring system. <i>Journal of Heart and Lung Transplantation</i> , 2015 , 34, 438-47	5.8	21
109	Hemodynamic factors associated with acute decompensated heart failure: part 2use in automated detection. <i>Journal of Cardiac Failure</i> , 2011 , 17, 366-73	3.3	21
108	Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. <i>American Journal of Cardiology</i> , 2018 , 121, 1400-1408	3	20
107	Impact of Tricuspid Regurgitation on Clinical Outcomes: The COAPT Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1305-1314	15.1	20
106	D-ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2015 , 9, 56-65	3.4	19
105	The Utility of a Wireless Implantable Hemodynamic Monitoring System in Patients Requiring Mechanical Circulatory Support. <i>ASAIO Journal</i> , 2018 , 64, 301-308	3.6	19
104	Predictors of short-term clinical response to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2017 , 19, 1056-1063	12.3	18
103	Pharmacologic therapies across the continuum of left ventricular dysfunction. <i>American Journal of Cardiology</i> , 2008 , 102, 21G-28G	3	18
102	Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up. <i>JACC: Heart Failure</i> , 2017 , 5, 204-212	7.9	18
101	The clinical characteristics of lower extremity lymphedema in 440 patients. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020 , 8, 851-859	3.2	17
100	Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial. <i>European Heart Journal</i> , 2017 , 38, 720-726	9.5	17
99	First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. <i>American Heart Journal</i> , 2018 , 204, 139-150	4.9	17
98	Ambulatory extra-aortic counterpulsation in patients with moderate to severe chronic heart failure. <i>JACC: Heart Failure</i> , 2014 , 2, 526-33	7.9	17
97	Design and rationale for the Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in non-responders and previously untreatable patients (SOLVE-CRT)	4.9	16

96	Endpoints in Heart Failure Drug Development: History and Future. JACC: Heart Failure, 2020, 8, 429-44	0 7.9	16
95	Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. <i>International Journal of Cardiology</i> , 2018 , 266, 187-1	9 2 .2	16
94	Current and future developments in the field of central sleep apnoea. <i>Europace</i> , 2016 , 18, 1123-34	3.9	16
93	The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics. <i>European Journal of Heart Failure</i> , 2015 , 17, 1075-83	12.3	16
92	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 528-538	12.3	16
91	Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2368-2378	15.1	16
90	A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure. <i>European Journal of Heart Failure</i> , 2021 , 23, 175-185	12.3	16
89	Health Status Changes and Outcomes in Patients With Heart Failure and Mitral Regurgitation: COAPT Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2099-2106	15.1	15
88	The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study design. <i>American Heart Journal</i> ,	4.9	15
87	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 136-147	12.3	15
8 ₇	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. <i>European</i>	12.3	15 15
	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 136-147 Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with	12.3	
86	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 136-147 Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers. <i>Congestive Heart Failure</i> , 2005 , 11, 59-64 Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With		15
86	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 136-147 Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers. <i>Congestive Heart Failure</i> , 2005 , 11, 59-64 Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016 , 28, 320-328 A Novel Wireless Left Atrial Pressure Monitoring System for Patients with Heart Failure, First	1.7	15 15
86 85 84	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 136-147 Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers. <i>Congestive Heart Failure</i> , 2005 , 11, 59-64 Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016 , 28, 320-328 A Novel Wireless Left Atrial Pressure Monitoring System for Patients with Heart Failure, First Ex-Vivo and Animal Experience. <i>Journal of Cardiovascular Translational Research</i> , 2019 , 12, 290-298 Preventing cardiovascular events in patients with diabetes mellitus. <i>American Journal of Medicine</i> ,	1.7	15 15 15
86 85 84 83	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. <i>European Journal of Heart Failure</i> , 2018, 20, 136-147 Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers. <i>Congestive Heart Failure</i> , 2005, 11, 59-64 Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016, 28, 320-328 A Novel Wireless Left Atrial Pressure Monitoring System for Patients with Heart Failure, First Ex-Vivo and Animal Experience. <i>Journal of Cardiovascular Translational Research</i> , 2019, 12, 290-298 Preventing cardiovascular events in patients with diabetes mellitus. <i>American Journal of Medicine</i> , 2004, 116 Suppl 5A, 39S-46S Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes: A Secondary Analysis of the COAPT Trial. <i>JAMA</i>	1.7 3·3 2.4	15 15 15
86 85 84 83 82	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 136-147 Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers. <i>Congestive Heart Failure</i> , 2005 , 11, 59-64 Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016 , 28, 320-328 A Novel Wireless Left Atrial Pressure Monitoring System for Patients with Heart Failure, First Ex-Vivo and Animal Experience. <i>Journal of Cardiovascular Translational Research</i> , 2019 , 12, 290-298 Preventing cardiovascular events in patients with diabetes mellitus. <i>American Journal of Medicine</i> , 2004 , 116 Suppl 5A, 39S-46S Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes: A Secondary Analysis of the COAPT Trial. <i>JAMA Cardiology</i> , 2021 , 6, 427-436 Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial. <i>Journal of the American Heart</i>	1.7 3·3 2·4 16.2	15 15 15 14 14

78	Transcatheter Mitral Valve Repair in Patients With and Without Cardiac Resynchronization Therapy: The COAPT Trial. <i>Circulation: Heart Failure</i> , 2020 , 13, e007293	7.6	12
77	Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure: COAPT Trial. <i>Circulation</i> , 2021 , 144, 426-4	43 ^{16.7}	12
76	Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure: DRIPS. <i>Circulation: Heart Failure</i> , 2020 , 13, e006731	7.6	11
75	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis. Journal of Clinical Sleep Medicine, 2019 , 15, 1747-1755	3.1	11
74	Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. <i>American Heart Journal</i> , 2020 , 219, 1-8	4.9	11
73	Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes. Journal of the American College of Cardiology, 2018 , 71, 1325-1333	15.1	10
72	Cardiac resynchronization therapy for the management of chronic heart failure. <i>The American Heart Hospital Journal</i> , 2003 , 1, 55-61		10
71	Predictors of Clinical Response to Transcatheter Reduction of Secondary Mitral Regurgitation: The COAPT Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1007-1014	15.1	10
70	Baseline Functional Capacity and Transcatheter Mitral Valve Repair in Heart[Failure With Secondary Mitral[Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 2331-2341	5	10
69	Apneas of Heart Failure and Phenotype-Guided Treatments: Part One: OSA. <i>Chest</i> , 2020 , 157, 394-402	5.3	10
68	Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. <i>JACC: Heart Failure</i> , 2021 , 9, 1-12	7.9	10
67	Optimizer Smart in the treatment of moderate-to-severe chronic heart failure. <i>Future Cardiology</i> , 2020 , 16, 13-25	1.3	9
66	Pulmonary Hypertension in Transcatheter Mitral Valve Repair for Secondary Mitral Regurgitation: The COAPT Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2595-2606	15.1	9
65	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020 , 22, 2370-2379	12.3	9
64	Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes. <i>Nature and Science of Sleep</i> , 2021 , 13, 515-526	3.6	9
63	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. <i>European Journal of Heart Failure</i> , 2020 , 22, 2175-2186	12.3	8
62	Patient Perceptions on Facilitating Follow-Up After Heart Failure Hospitalization. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	7
61	Future research prioritization in cardiac resynchronization therapy. <i>American Heart Journal</i> , 2020 , 223, 48-58	4.9	7

(2021-2018)

A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. <i>American Heart Journal</i> , 2018 , 199, 51-58	4.9	7
Current treatment approaches and trials in central sleep apnea. <i>International Journal of Cardiology</i> , 2016 , 206 Suppl, S22-7	3.2	7
Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. <i>American Heart Journal</i> , 2020 , 230, 93-97	4.9	7
Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e010300	6	7
Population Study of Urban, Rural, and Semiurban Regions for the Detection of Endovascular Disease and Prevalence of Risk Factors and Holistic Intervention Study: Rationale, Study Design, and Baseline Characteristics of PURSE-HIS. <i>Global Heart</i> , 2015 , 10, 281-9	2.9	7
Cardiac resynchronization therapy: a review of clinical trials and criteria for identifying the appropriate patient. <i>Reviews in Cardiovascular Medicine</i> , 2003 , 4 Suppl 2, S30-7	3.9	7
Novel non-pharmacological approaches to heart failure. <i>Journal of Cardiovascular Translational Research</i> , 2014 , 7, 263-5	3.3	6
Cardiac resynchronization therapy is important for all patients with congestive heart failure and ventricular dyssynchrony. <i>Circulation</i> , 2006 , 114, 2692-8; discussion 2698	16.7	6
Right Ventricular-Pulmonary Arterial Coupling in Patients With HF Secondary MR: Analysis From the COAPT Trial. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 2231-2242	5	6
Remote Hemodynamic-Guided Therapy of Patients With Recurrent Heart Failure Following Cardiac Resynchronization Therapy. <i>Journal of the American Heart Association</i> , 2021 , 10, e017619	6	6
Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 931-956	15.1	6
The role of implantable hemodynamic monitors to manage heart failure. <i>Heart Failure Clinics</i> , 2015 , 11, 183-9	3.3	5
Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy: Analysis of the 5-Year Follow-Up From the REVERSE Study. JACC: Heart Failure, 2015 , 3, 691-700	7.9	5
Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education. <i>American Journal of Medicine</i> , 2018 , 131, 974-978	2.4	5
Optimization of Cardiac Resynchronization Devices Using Acoustic Cardiography: A Comparison to Echocardiography. <i>Congestive Heart Failure</i> , 2006 , 12, 25-31		5
Effect of Mitral Valve Gradient After MitraClip on Outcomes in Secondary Mitral Regurgitation: Results From the COAPT Trial. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 879-889	5	5
Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial. <i>ESC Heart Failure</i> , 2021 , 8, 3472-3482	3.7	5
Sex-Specific Outcomes of Transcatheter Mitral-Valve Repair and Medical Therapy for Mitral Regurgitation in Heart[Failure. <i>JACC: Heart Failure</i> , 2021 , 9, 674-683	7.9	5
	prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. American Heart Journal, 2018, 199, 51-58 Current treatment approaches and trials in central sleep apnea. International Journal of Cardiology, 2016, 206 Suppl, 522-7 Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. American Heart Journal, 2020, 230, 93-97 Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to Mitracilip in the CoAPT Trial. Circulation: Cardiovascular Interventions, 2021, 14, e010300 Population Study of Urban, Rural, and Semiurban Regions for the Detection of Endovascular Disease and Prevalence of Risk Factors and Holistic Intervention Study: Rationale, Study Design, and Baseline Characteristics of PURSE-HIS. Clobal Heart, 2015, 10, 281-9 Cardiac resynchronization therapy: a review of clinical trials and criteria for identifying the appropriate patient. Reviews in Cardiovascular Medicine, 2003, 4 Suppl 2, 530-7 Novel non-pharmacological approaches to heart failure. Journal of Cardiovascular Translational Research, 2014, 7, 263-5 Cardiac resynchronization therapy is important for all patients with congestive heart failure and ventricular dyssynchrony. Circulation, 2006, 114, 2692-8; discussion 2698 Right Ventricular-Pulmonary Arterial Coupling in Patients With HF Secondary MR: Analysis From the COAPT Trial. JACC: Cardiovascular Interventions, 2021, 14, 2231-2242 Remote Hemodynamic-Guided Therapy of Patients With Recurrent Heart Failure Following Cardiac Resynchronization Therapy. Journal of the American Heart Association, 2021, 10, e017619 Device Therapy in Chronic Heart[Failure: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 2021, 78, 931-956 The role of implantable hemodynamic monitors to manage heart failure. Heart Failure Receiving Cardiac Resynchronization Therapy. Anal	prevention of symptomatic atrial Fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. American Heart Journal, 2018, 199, 51-58 Current treatment approaches and trials in central sleep apnea. International Journal of Cardiology, 2016, 206 Suppl, S22-7 Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. American Heart Journal, 2020, 230, 93-97 Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. American Heart Journal, 2020, 230, 93-97 Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. American Heart Journal, 2020, 230, 93-97 Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to Mitral Clip in the CoAPT Trial. Circulation. Cardiovascular Interventions, 2021, 14, e010300 Population Study of Urban, Rural, and Semiurban Regions for the Detection of Endovascular Disease and Prevalence of Risk Factors and Holistic Interventions, 2021, 14, e010300 Population Study of Urban, Rural, and Semiurban Regions for the Detection of Endovascular Disease and Prevalence of Risk Factors and Holistic Interventions Seasons of the Intervention Interventions of Cardiac and Prevalence of Risk Factors and Holistic Interventions for the Intervention Intervention Interventions and Prevalence of Risk Factors and Holistic Interventions and Cardiac Resynchronization Therapy. Accordance of Cardiovascular Interventions, 2021, 14, 2231-2242 Search Seasons of Cardiac Resynchronic Heart Pailure, 100-11, 14, 2231-2242 Device Therapy in Chronic Heart Pailure, 100-11, 14, 2231-2242 The role of implantable hemodynamic monitors to manage heart failure. Heart Failure Clinics, 2015, 11, 183-9 Device Therapy in Chronic Heart Pailure, 100-

42	The Role of Implantable Hemodynamic Monitors to Manage Heart Failure. <i>Cardiology Clinics</i> , 2017 , 35, 273-279	2.5	4
41	In-Hospital Management of Sleep Apnea During Heart Failure Hospitalization: A Randomized Controlled Trial. <i>Journal of Cardiac Failure</i> , 2020 , 26, 705-712	3.3	4
40	Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT. <i>European Journal of Heart Failure</i> , 2017 , 19, 80-87	12.3	4
39	Treatment of anemia with darbepoetin alfa in heart failure. <i>Congestive Heart Failure</i> , 2010 , 16, 87-95		4
38	Abstract 16744: Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure Hospitalizations and All-Cause 30-Day Readmissions in Medicare-Eligible Patients With NYHA Class III Heart Failure: Results From the CHAMPION Trial. <i>Circulation</i> , 2014 , 130,	16.7	4
37	Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. <i>JACC: Heart Failure</i> , 2020 , 8, 961-972	7.9	4
36	Feasibility of remote speech analysis in evaluation of dynamic fluid overload in heart failure patients undergoing haemodialysis treatment. <i>ESC Heart Failure</i> , 2021 , 8, 2467-2472	3.7	4
35	Design of a "Lean" Case Report Form for Heart[Failure Therapeutic Development. <i>JACC: Heart Failure</i> , 2019 , 7, 913-921	7.9	3
34	Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation <i>Heart</i> , 2022 ,	5.1	3
33	Remote Speech Analysis in the Evaluation of Hospitalized Patients With Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2022 , 10, 41-49	7.9	3
32	Impact of COPD on Outcomes After MitraClip for Secondary Mitral Regurgitation: The COAPT Trial. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 2795-2803	5	3
31	Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease. <i>Circulation: Heart Failure</i> , 2021 , 14, e007564	7.6	3
30	Wireless Hemodynamic Monitoring in Patients with Heart Failure. <i>Current Heart Failure Reports</i> , 2021 , 18, 12-22	2.8	3
29	Dose Response of Blockers in Adrenergic Receptor Polymorphism Genotypes. <i>Circulation Genomic and Precision Medicine</i> , 2018 , 11, e002210	5.2	3
28	Prognostic Importance of Health Status Versus Functional Status in Heart[Failure and Secondary Mitral Regurgitation. <i>JACC: Heart Failure</i> , 2021 , 9, 684-692	7.9	3
27	Cardiac computed tomography assessment of the near term impact of percutaneous ventricular restoration therapy (parachute(1)) on mitral valve geometry. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 88, E45-51	2.7	2
26	Remote heart failure monitoring. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 556-6	5 4 2.1	2
25	Switching to evidence-based once-daily beta-blockers for improved adherence to medication across the continuum of post-myocardial infarction left ventricular dysfunction and heart failure. <i>Congestive Heart Failure</i> , 2008 , 14, 272-80		2

(2021-2021)

24	Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2021 , 14, e008212	7.6	2
23	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021 , 237, 45-53	4.9	2
22	Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. <i>Circulation</i> , 2021 , 144, 1265-126	7 ^{16.7}	2
21	The Use of MitraClip in Secondary Mitral Regurgitation and Heart Failure. <i>Cardiovascular Revascularization Medicine</i> , 2020 , 21, 1606-1612	1.6	1
20	Evaluating the quality of implantation of percutaneous ventricular restoration device (Parachute) by cardiac computed tomography. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, E104-E117	1 ^{2.7}	1
19	The Davis Heart and Lung Research Institute: Building a Sustainable Platform for Translation. <i>Circulation Research</i> , 2017 , 120, 1068-1071	15.7	1
18	Cardiac Resynchronization Therapy in Heart Failure. <i>Annals of Internal Medicine</i> , 2005 , 142, 307	8	1
17	Age-Related Outcomes After Transcatheter Mitral Valve Repair in Patients With Heart Failure: Analysis From COAPT <i>JACC: Cardiovascular Interventions</i> , 2022 , 15, 397-397	5	1
16	Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial <i>European Heart Journal</i> , 2022 ,	9.5	1
15	Phrenic nerve stimulation in patients with central sleep apnea: a single-center experience from pilot and pivotal trials evaluating the remed System. <i>Kardiologia Polska</i> , 2019 , 77, 553-560	0.9	1
14	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1334-1349	6.1	1
13	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the Arg389Arg Genotype. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021 , 14, e009591	6.4	1
12	Pulmonary Artery Pressure Monitoring Effectively Guides Management to Reduce Heart Failure Hospitalizations in Obesity. <i>JACC: Heart Failure</i> , 2021 , 9, 784-794	7.9	1
11	Comprehensive Pharmacologic Management Strategies for Heart Failure15-34		1
10	Diabetes, hypertension, and renal insufficiency in post-myocardial infarction cardiovascular risk. <i>Reviews in Cardiovascular Medicine</i> , 2003 , 4 Suppl 3, S30-6	3.9	1
9	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week <i>Journal of the American College of Cardiology</i> , 2022 , 79, 504-510	15.1	O
8	Who and when to clip: that is the question. <i>European Journal of Heart Failure</i> , 2020 , 22, 20-22	12.3	0
7	Direct Interstitial Decongestion in an Animal Model of Acute-on-Chronic Ischemic Heart Failure. JACC Basic To Translational Science, 2021, 6, 872-881	8.7	O

6	Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart Failure: COAPT Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 559-567	7.9	O
5	Left Ventricular Global Longitudinal Strain as a Predictor of Outcomes in Patients with Heart Failure with Secondary Mitral Regurgitation: The COAPT Trial. <i>Journal of the American Society of Echocardiography</i> , 2021 , 34, 955-965	5.8	0
4	Imaging Device Therapy: Essentials for the Imager. Heart Failure Clinics, 2019, 15, 305-320	3.3	
3	Dose-limiting, adverse event-associated bradycardia with Eblocker treatment of atrial fibrillation in the GENETIC-AF trial <i>Heart Rhythm O2</i> , 2022 , 3, 40-49	1.5	
2		3.9	